Stock 1952 EVEREST MEDICINES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Everest Medicines Limited

Equities

1952

KYG3224E1061

Delayed Hong Kong S.E.
Other stock markets
 11:57:43 2024-04-24 pm EDT 		5-day change 1st Jan Change
24.2 HKD +2.98% Intraday chart for Everest Medicines Limited +5.68% +15.79%
05:11am Everest Medicines' Loss Widens in 2023 MT
Mar. 28 Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Everest Medicines Limited

Price target over the last 5 years

History of analyst recommendation changes

0cca5d3397c9e2a31e6510bd777912c.fgRTNAf99yJk38VpFWYmbKzDFXRQJ0j4rLFY_IvfYOg.MmgSBG-bnFAGvowgVAxyXdX3dyUzFzDNw-AVu_7sKIFHThxBfqmVRDCskA~8e75072987f899ac5ddb8f043a1bfe03

Analyst Recommendations on Everest Medicines Limited

Everest Medicines and Gilead Sciences Jointly Announce Phase 2B Study of Sacituzumab Govitecan Conducted in China of Patients with Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint CI
EVEREST MEDICINES : Nomura Starts Everest Medicines at Buy With HK$110 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
21.74 CNY
Average target price
25.92 CNY
Spread / Average Target
+19.22%
High Price Target
36.92 CNY
Spread / Highest target
+69.82%
Low Price Target
22.21 CNY
Spread / Lowest Target
+2.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Everest Medicines Limited

Nomura

Ratings for Everest Medicines Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 1952 Stock
  4. Consensus Everest Medicines Limited